Vertex Reports meta-analysis Data for Iptacopan in Rheumatoid arthritis

Vertex today announced meta-analysis results for iptacopan in patients with rheumatoid arthritis. The study demonstrated that iptacopan reduces adverse events compared to standard of care or placebo. These results provide important insights into the treatment of rheumatoid arthritis and support the continued development of iptacopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.